101
|
Joly C, Weber B. Un désir qui devient réalité: grossesse après chimiothérapie d’un cancer du sein. ONCOLOGIE 2012. [DOI: 10.1007/s10269-012-2173-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
102
|
Montag C, Reuter M, Weber B, Markett S, Schoene-Bake JC. Individual differences in trait anxiety are associated with white matter tract integrity in the left temporal lobe in healthy males but not females. Neuroscience 2012; 217:77-83. [PMID: 22609931 DOI: 10.1016/j.neuroscience.2012.05.017] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2012] [Revised: 04/27/2012] [Accepted: 05/06/2012] [Indexed: 11/17/2022]
Abstract
The temporal lobe plays a major role in anxiety and depression disorders and is also of importance for trait anxiety in the non-pathological range. The present study investigates self-report data of personality dimensions linked to trait anxiety in the context of white matter tract integrity in the temporal lobes of the human brain in a large sample of N=110 healthy participants. The results show that especially in men values for fractional anisotropy of several white matter tracts in the temporal lobe of the left hemisphere correlate substantially with individual differences in trait anxiety (depending on the tract investigated between .40 and .49). The present study shows that not only data from functional magnetic resonance imaging (fMRI), but also from structural diffusion tensor imaging (DTI) provide interesting insights into the biological foundation of human personality traits.
Collapse
|
103
|
Vieths S, Barber D, Chapman M, Costanzo A, Daas A, Fiebig H, Hanschmann KM, Hrabina M, Kaul S, Ledesma A, Moingeon P, Reese G, Schörner C, van Ree R, Weber B, Buchheit KH. Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement. Results from feasibility studies. PHARMEUROPA BIO & SCIENTIFIC NOTES 2012; 2012:118-134. [PMID: 23327896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The potency of allergen extracts is determined as total allergenic activity without consideration of their composition and the units differ from one manufacturer to another, making it very difficult to compare the different products. Recently, purified major allergens have been obtained by recombinant DNA technology and produced under Good Manufacturing Practice (GMP) conditions. In principle, such recombinant allergens could be established as reference standards and could help for the standardisation of the major allergen content of allergen extracts. Two recombinant major allergens, one from birch pollen, rBet v 1, and one from Timothy grass pollen, Phl p 5a, have been selected at the end of the CREATE programme as a potential starting point for the establishment as European Pharmacopoeia (Ph. Eur.) Reference Standards through a project run by the Biological Standardisation Programme (BSP) of the European Directorate for the Quality of Medicines & HealthCare (EDQM). To this end, bulk candidate recombinant materials, produced under GMP conditions, were procured from two European manufacturers and subsequently formulated and lyophilised. Four ELISA systems from three different manufacturers were included in the project, two for Bet v 1 and two for Phl p 5a with the aim of establishing reference methods for determination of the respective major antigens both in natural allergen extracts as well as in recombinant allergen products. The project was run in 3 phases: a preparatory and preliminary testing phase (feasibility phase or Phase 1), an extended feasibility phase carried out in 3 laboratories (Phase 2) to confirm the transferability of the methods and an international collaborative study with a large number of participating laboratories (Phase 3). This article describes the work done in Phase 1 and Phase 2, i.e. the physico-chemical and biological characterisation of the recombinant candidate reference standards, the assessment of their suitability for the intended purpose as well as the evaluation of the candidate ELISA systems. The results show that both candidate reference standards are suitable for the intended purpose. In addition, three out of the four ELISA systems that were included in the preliminary phase were found to be appropriate for further evaluation in the collaborative study which was organised in 2011. The results of the collaborative study will be published separately.
Collapse
|
104
|
Rudorf S, Preuschoff K, Weber B. Risk Evaluation Signals Code for Economic Risk Preferences. KLIN NEUROPHYSIOL 2012. [DOI: 10.1055/s-0032-1301440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
105
|
Bürger C, Schöne-Bake JC, Johnson EJ, Weber EU, Weber B. White matter integrity predicts domain-specific risk perception: Insights from diffusion tensor imaging. KLIN NEUROPHYSIOL 2012. [DOI: 10.1055/s-0032-1301611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
106
|
Rüber T, Lindenberg R, von Lehe M, Weber B, Elger CE, Schoene-Bake JC. Diffusivitätscharakteristika des ipsiläsionellen Nucleus Ruber in Patienten nach Hemisphärektomie. KLIN NEUROPHYSIOL 2012. [DOI: 10.1055/s-0032-1301556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
107
|
Strang S, Utikal V, Falk A, Fischbacher U, Weber B. Neural correlates of receiving an apology. KLIN NEUROPHYSIOL 2012. [DOI: 10.1055/s-0032-1301615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
108
|
Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Ann Oncol 2012; 23:346-52. [DOI: 10.1093/annonc/mdr149] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
109
|
Bonrath E, Rijcken E, Fritz M, Weber B, Senninger N, Grantcharov T. Laparoscopic Simulation Training? Does Timing Impact the Quality of Skills Acquisition? J Surg Res 2012. [DOI: 10.1016/j.jss.2011.11.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
110
|
Cavalcanti AB, Othero JC, Mouro JC, Silva KN, Victor ES, Kodama AA, Berwanger O, Weber B, Mota LH. Effects of a multifaceted quality improvement intervention in reducing mortality and bloodstream infection in ICUs: insights from the QUALITI initiative. Crit Care 2012. [PMCID: PMC3363483 DOI: 10.1186/cc10672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
111
|
Emmert MY, Wolint P, Weber B, Falk V, Hoerstrup SP. Characterization, differentiation and 3D formation of human mesenchymal stem cells for advanced cardaac stem cell therapies. Thorac Cardiovasc Surg 2012. [DOI: 10.1055/s-0031-1297637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
112
|
Kiekhaefer CM, Weber B, Huggins M, Gorichanaz C, Nehring JA, DeLuca HF. 2α-Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D(3) protects the insulin 2 knockout non-obese diabetic mouse from developing type 1 diabetes without hypercalcaemia. Clin Exp Immunol 2012; 166:325-32. [PMID: 22059989 DOI: 10.1111/j.1365-2249.2011.04481.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Type 1 diabetes (T1D) is an autoimmune disease that destroys the insulin-producing beta-islet cells of the pancreas. Currently, there are no treatment modalities for prevention of T1D, and the mechanisms influencing disease inception and early progression are not well understood. We have used the insulin 2(-/-) non-obese diabetic (Ins2(-/-) NOD) model to study stages of T1D and to examine the protective effects of a potent analogue of 1α,25-dihydroxyvitamin D(3), 2α-methyl-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2AMD). Pancreatic tissues from control and 2AMD-treated Ins2(-/-) NOD mice were obtained weekly from 5 to 16 weeks of age. Using immunohistochemical (IHC) analysis, samples were analysed for changes in beta cell survival, islet structure and T cell invasion. Weekly intraperitoneal glucose tolerance tests (IPGTT) were performed to assess comparative beta cell function in control and treated animals. IHC demonstrated progressive beta cell destruction in control mice. In contrast, 2AMD treatment preserved islet cell architecture, arrested intra-islet T cell invasion and prevented the transition from insulitis to diabetes. IPGTT results revealed progressive impairment of beta cell function with increasing age in control mice, while 2AMD treatment resulted in normal beta function throughout the study. These results demonstrate that the Ins2(-/-) NOD model provides a rapid and effective method for studying T1D and for assessing efficacy of anti-diabetic agents.
Collapse
|
113
|
Weber B, Mahapatra S, Ryu H, Lee S, Fuhrer A, Reusch TCG, Thompson DL, Lee WCT, Klimeck G, Hollenberg LCL, Simmons MY. Ohm’s Law Survives to the Atomic Scale. Science 2012; 335:64-7. [DOI: 10.1126/science.1214319] [Citation(s) in RCA: 263] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
114
|
Weber B, Marx S, Gehring H, Nestler B. Direct modulation of pulse oximetry probe light signals using a digital micromirror array for instrumental calibration of optical sensors. BIOMED ENG-BIOMED TE 2012. [DOI: 10.1515/bmt-2012-4046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
115
|
Kellner U, Renner A, Herbst S, Kellner S, Weinitz S, Weber B. Hereditäre Netzhautdystrophien. AUGENHEILKUNDE UP2DATE 2012. [DOI: 10.1055/s-0031-1280460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
116
|
Weber B. Neuroeconomics – Investigating the biological basis of human decision making. ROFO-FORTSCHR RONTG 2011. [DOI: 10.1055/s-0031-1295508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
117
|
Memon AA, Weber B, Winterdahl M, Jakobsen S, Meldgaard P, Madsen HHT, Keiding S, Nexo E, Sorensen BS. PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer 2011; 105:1850-5. [PMID: 22095231 PMCID: PMC3251890 DOI: 10.1038/bjc.2011.493] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background: We have previously developed 11C-erlotinib as a new positron emission tomography (PET) tracer and shown that it accumulates in epidermal growth factor receptor (EGFR)-positive lung cancer xenografts in mice. Here, we present a study in patients with non-small cell lung cancer (NSCLC) investigating the feasibility of 11C-erlotinib PET as a potential method for the identification of lung tumours accumulating erlotinib. Methods: Thirteen patients with NSCLC destined for erlotinib treatment were examined by contrast-enhanced computed tomography (CT), 11C-erlotinib PET/low-dose CT and 18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET/low-dose CT before start of the erlotinib treatment. After 12 weeks treatment, they were examined by 18F-FDG PET/contrast-enhanced CT for the assessment of clinical response. Results: Of the 13 patients included, 4 accumulated 11C-erlotinib in one or more of their lung tumours or lymph-node metastases. Moreover, 11C-erlotinib PET/CT identified lesions that were not visible on 18F-FDG PET/CT. Of the four patients with accumulation of 11C-erlotinib, one died before follow-up, whereas the other three showed a positive response to erlotinib treatment. Three of the nine patients with no accumulation died before follow-up, four showed progressive disease while two had stable disease after 12 weeks of treatment. Conclusion: Our data show a potential for 11C-erlotinib PET/CT for visualizing NSCLC lung tumours, including lymph nodes not identified by 18F-FDG PET/CT. Large clinical studies are now needed to explore to which extent pre-treatment 11C-erlotinib PET/CT can predict erlotinib treatment response.
Collapse
|
118
|
Weber B, Zeisberger S, Hoerstrup S. Characterization and evaluation of fetal stem cells used for tissue engineering. Placenta 2011. [DOI: 10.1016/j.placenta.2011.07.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
119
|
Wagner J, Weber B, Urbach H, Elger CE, Huppertz HJ. Morphometric MRI analysis improves detection of focal cortical dysplasia type II. Brain 2011; 134:2844-54. [DOI: 10.1093/brain/awr204] [Citation(s) in RCA: 150] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
120
|
Kremer J, Langlet J, Skraber S, Weicherding P, Weber B, Cauchie HM, De Landtsheer S, Even J, Muller C, Hoffmann L, Mossong J. Genetic diversity of noroviruses from outbreaks, sporadic cases and wastewater in Luxembourg 2008–2009. Clin Microbiol Infect 2011; 17:1173-6. [DOI: 10.1111/j.1469-0691.2010.03407.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
121
|
Tschoep-Lechner K, Dieterle N, Abdel-Rahman S, Lindner L, Salat C, Ehrke S, Weber B, Bruns CJ, Heinemann V, Mansmann U, Issels RD. Regional hyperthermia (RHT) as an innovative treatment component: RHT combined with gemcitabine (G) and cisplatin (CIS) in G-pretreated advanced pancreatic cancer (APC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
122
|
Pautier P, Floquet A, Gladieff L, Berton-Rigaud D, Piperno-Neumann S, Selle F, Guillemet C, Ray-Coquard IL, Weber B, Duvillard P, Haie-Meder C, Rey A. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
123
|
Nabholtz J, Weber B, Mouret-Reynier M, Gligorov J, Coudert BP, Vanlemmens L, Petit T, Tredan O, Van Praagh-Doreau I, Dubray-Longeras P, Ferriere J, Nayl B, Tubiana-Mathieu N, Jouannaud C, Devaud H, Abrial C, Planchat E, Chalabi N, Penault-Llorca FM, Chollet PJM. Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11574] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
124
|
Weber B, Zeisberger SM, Hoerstrup SP. Prenatally harvested cells for cardiovascular tissue engineering: fabrication of autologous implants prior to birth. Placenta 2011; 32 Suppl 4:S316-9. [PMID: 21575988 DOI: 10.1016/j.placenta.2011.04.001] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2011] [Accepted: 04/04/2011] [Indexed: 12/17/2022]
Abstract
Using the principal of tissue engineering, several groups have demonstrated the feasibility of creating heart valves, blood vessels, and myocardial structures using autologous cells and biodegradable scaffold materials. In the current cardiovascular clinical scenario, the main medical need for a tissue engineering solution is in the field of pediatric applications treating congenital heart disease. In these young patients, the introduction of autologous viable and growing replacement structures, such as tissue engineered heart valves and vessels, would substantially reduce today's severe therapeutic limitations, which are mainly due to the need for repeat reoperations to adapt the current artificial prostheses to somatic growth. Based on high resolution imaging techniques, an increasing number of defects are diagnosed already prior to birth around week 20. For interventions, cells should be obtained already during pregnancy to provide tissue engineered implants either at birth or even prenatally. In our recent studies human fetal mesenchymal stem cells were isolated from routinely sampled prenatal amniotic fluid or chorionic villus specimens and expanded in vitro. Fresh and cryopreserved samples were used. After phenotyping and genotyping, cells were seeded onto synthetic biodegradable scaffolds and conditioned in a bioreactor. Leaflets were endothelialized with either amniotic fluid- or umbilical cord blood-derived endothelial progenitor cells and conditioned. Resulting tissues were analyzed by histology, immunohistochemistry, biochemistry (amounts of extracellular matrix, DNA), mechanical testing, and scanning electron microscopy (SEM) and were compared with native neonatal heart valve leaflets. Genotyping confirmed their fetal origin, and fresh versus cryopreserved cells showed comparable myofibroblast-like phenotypes. Neo-tissues exhibited organization, cell phenotypes, extracellular matrix production, and DNA content comparable to their native counterparts. Leaflet surfaces were covered with functional endothelia. SEM showed morphologically cellular distribution throughout the polymer and smooth surfaces. Mechanical profiles approximated those of native heart valves. These in vitro studies demonstrated the principal feasibility of using various human cell types isolated from fetal sources for cardiovascular tissue engineering. Umbilical cord blood-, amniotic fluid- and chorionic villi-derived cells have shown promising potential for the clinical realization of this congenital tissue engineering approach. Based on these results, future research must aim at further investigation as well as preclinical evaluation of prenatally harvested stem- or progenitor cells with regard to their potential for clinical use.
Collapse
|
125
|
Emmert MY, Weber B, Theusinger OM, Hoerstrup SP, Falk V, Grünenfelder J, Plass A. Delayed two-step free wall rupture of the right and left ventricular wall after myocardial infarction. Thorac Cardiovasc Surg 2011; 59:248-50. [PMID: 21455883 DOI: 10.1055/s-0030-1250503] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
We present a 68-year-old female who suffered extensive complications after severe myocardial infarction (MI) in the circumflex (CX) territory. At 24 hours after the initial event, the patient presented with a covered right ventricular free wall rupture (FWR) which was followed by a rupture of the left posterior wall ten days later. We report here on a rare case of delayed two-step biventricular FWR after severe MI in the CX territory.
Collapse
|